Mosaic ImmunoEngineering Announces Director Changes
Ticker: CPMV · Form: 8-K · Filed: Apr 19, 2024 · CIK: 836564
| Field | Detail |
|---|---|
| Company | Mosaic Immunoengineering INC. (CPMV) |
| Form Type | 8-K |
| Filed Date | Apr 19, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-change, officer-compensation
TL;DR
Mosaic ImmunoEngineering swapped a director and updated officer compensation.
AI Summary
Mosaic ImmunoEngineering Inc. announced on April 17, 2024, the departure of Director Dr. David J. Earp and the appointment of Dr. Robert J. Valeri as a new director. The company also reported on compensatory arrangements for its officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine board and officer changes and compensation, which are standard corporate events.
Key Players & Entities
- Mosaic ImmunoEngineering Inc. (company) — Registrant
- Dr. David J. Earp (person) — Departing Director
- Dr. Robert J. Valeri (person) — Appointed Director
FAQ
Who is the departing director and when did their departure become effective?
Dr. David J. Earp departed as a director, with the earliest event reported as April 17, 2024.
Who has been appointed as a new director?
Dr. Robert J. Valeri has been appointed as a new director.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is April 17, 2024.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the SIC code for Mosaic ImmunoEngineering Inc.?
The Standard Industrial Classification code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 423 words · 2 min read · ~1 pages · Grade level 12.1 · Accepted 2024-04-19 10:55:47
Filing Documents
- mosaic_8k.htm (8-K) — 25KB
- 0001683168-24-002534.txt ( ) — 186KB
- cpmv-20240417.xsd (EX-101.SCH) — 3KB
- cpmv-20240417_lab.xml (EX-101.LAB) — 33KB
- cpmv-20240417_pre.xml (EX-101.PRE) — 22KB
- mosaic_8k_htm.xml (XML) — 3KB
02 Departure
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Mosaic ImmunoEngineering, Inc. (the "Company") is deeply saddened to announce that director Ms. Gloria Felcyn passed away on April 17, 2024. Ms. Felcyn had been an independent director on the Board of Directors of the Company (the "Board") since 2002 and served on the Audit Committee, the Compensation Committee and the Corporate Governance and Nominating Committee of the Board. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mosaic ImmunoEngineering, Inc. Date: April 19, 2024 By: /s/ Steven King Steven King President and Chief Executive Officer, Director 3